Kim R. Tsuchimoto - Dec 31, 2023 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer, Director
Signature
/s/ Kim R. Tsuchimoto
Stock symbol
MNPR
Transactions as of
Dec 31, 2023
Transactions value $
-$1,557
Form type
4
Date filed
1/3/2024, 07:34 PM
Previous filing
Oct 3, 2023
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +9.96K +26.21% 47.9K Dec 31, 2023 Direct F1
transaction MNPR Common Stock Tax liability -$1.39K -4.07K -8.5% $0.34 43.9K Dec 31, 2023 Direct F2
transaction MNPR Common Stock Options Exercise +1.23K +2.81% 45.1K Jan 1, 2024 Direct F1
transaction MNPR Common Stock Tax liability -$172 -505 -1.12% $0.34 44.6K Jan 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -9.96K -9.44% $0.00 95.6K Dec 31, 2023 Common Stock 9.96K Direct F1, F3, F4, F5
transaction MNPR Restricted Stock Units Options Exercise $0 -1.23K -1.29% $0.00 94.3K Jan 1, 2024 Common Stock 1.23K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3 On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F4 On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5 On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6 On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.